Dr. Nicholas James shares why it’s important to identify which patients with high-risk, non-metastatic prostate cancer will ...

J&J is looking to add a hormone-sensitive indication to its prostate cancer therapy, which was originally approved in 2023.

Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved ...

During a live event, Jahan Aghalar, MD, discussed key NCCN-recommended oral therapies and landmark trials for metastatic prostate cancer.

Prostate cancer is one of the most common malignancies in men globally. Hormonal therapies targeting the androgen–androgen receptor axis have significantly delayed disease progression. However, drug ...

Prostate cancer is the second most common cancer in men. In 2023, it’s estimated that there will be 288,300 new cases of prostate cancer and 34,700 deaths, according to the American Cancer Society .

Riekhof F, Yan Y, Bennett CL, et al. Hospitalizations among veterans treated for metastatic prostate cancer with abiraterone or enzalutamide. Clin Genitourin Cancer . Published online July 11 ...

AI test could help to cut the risk of dying from prostate cancer by half, study suggests. By SHAUN WOOLLER HEALTH EDITOR. Published: 19:02 EDT, 29 May 2025 | Updated: 20:02 EDT, 29 May 2025 ...

Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, has updated its award-winning ArteraAI Prostate Test with new insights to help ...

Background: Estimations are that 8-18% of newly diagnosed cancer patients have Type 2 Diabetes Mellitus (T2DM). Current guidelines offer no clarification on the choice of therapy for prostate cancer ...

The NDA for niraparib plus abiraterone acetate and prednisone has been submitted ... as a first-line targeted treatment for patients with metastatic castration-resistant prostate cancer with BRCA ...